methylprednisolone sodium succinate

P=N/A, N=70, Completed, Xuanwu Hospital, Beijing | Recruiting --> Completed

P2, N=80, Recruiting, University of Colorado, Denver | Not yet recruiting --> Recruiting

P2, N=40, Enrolling by invitation, Uppsala University Hospital | Trial completion date: May 2026 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Apr 2028

P2, N=16, Not yet recruiting, Mayo Clinic

P2, N=80, Not yet recruiting, University of Colorado, Denver

P3, N=3200, Recruiting, Children's Hospital of Fudan University | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2024

P1/2, N=55, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Sep 2024 --> Sep 2025

P3, N=300, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P3, N=50, Not yet recruiting, The Hospital for Sick Children

P1/2, N=24, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | N=10 --> 24

P2, N=200, Recruiting, AHS Cancer Control Alberta | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

Intravenous methylprednisolone (IVMP) and plasma exchange resulted in partial improvement...In each episode, IVMP was to be partially effective with anti-IgE AAb reduction. Anti-IgE AAb may be a reasonable clinical indicator of increased disease activity in the sero-negative NMOSD associated with AD.

P2, N=1, Terminated, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N=30 --> 1 | Trial completion date: Oct 2021 --> Sep 2024 | Unknown status --> Terminated | Trial primary completion date: Oct 2021 --> Sep 2024; Participants recruitment failure

We experienced a case of pathologically diagnosed neurolymphomatosis with autonomic dysfunction associated with CLPD-NK. In cases of subacute to chronic autonomic dysfunction, paraneoplastic neuropathy, amyloidosis, and autoimmune autonomic ganglionopathy are considered; however neurolymphomatosis caused by CLPD-NK, an important cause of autonomic dysfunction, is not. In difficult to make diagnosis, aggressive nerve biopsy is required.

P3, N=1200, Active, not recruiting, Centre Hospitalier Universitaire Dijon | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2027 --> Feb 2024

Based on radiographic findings, a diagnosis of paraneoplastic LETM was made and he was treated acutely with IV methylprednisolone followed by a quick oral prednisone taper. However, he subsequently relapsed and symptomatically worsened while on rituximab therapy...Our observation of sustained disease response in this patient may support a role for concurrent BTK and BCL2 inhibition in paraneoplastic myelitis associated with B-cell lymphoproliferative disorders. However, this observation needs to be validated in larger cohort studies and potentially in clinical trials if further data are supportive.

In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases.

P=N/A, N=50, Recruiting, Xuanwu Hospital, Beijing | Not yet recruiting --> Recruiting

He was started on intravenous methylprednisolone (subsequently transitioned to prednisone), methimazole, and metoprolol. Colchicine was subsequently added for the management of pericarditis and prednisone was continued (given concomitant thyroid disease) with a plan for tapering them off, per cardiology and endocrinology recommendations. A transthoracic echocardiogram revealed a small pericardial effusion...Thyroid ultrasound was nonsuggestive of Graves' disease. Thyrotoxicosis may present with a constellation of symptoms, including acute pericarditis. Timely recognition with EKG and echocardiography can aid in prompt management.

P=N/A, N=170, Completed, Xuanwu Hospital, Beijing | N=248 --> 170 | Trial completion date: Dec 2021 --> Jul 2024 | Trial primary completion date: Dec 2021 --> Jul 2024

P1, N=47, Completed, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Active, not recruiting --> Completed

P1, N=9, Terminated, University of Alabama at Birmingham | N=40 --> 9 | Active, not recruiting --> Terminated; no further funding to continue, investigator relocated, no replacement found to continue

P4, N=60, Recruiting, Aga Khan University | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Apr 2025

P4, N=150, Not yet recruiting, Third Affiliated Hospital, Sun Yat-Sen University

He presented multiple severe relapses despite complete thymoma resection, intravenous methylprednisolone with immunoglobulins or plasmapheresis, and mycophenolate mofetil. Second-line immunotherapy with rituximab was successful to alleviate symptoms and normalize the EEG and MRI after identification of anti-GABAA receptor antibodies on more comprehensive neural antibody testing for autoimmune encephalitis. This case demonstrates the complexity and importance of identifying pathogenic antibodies and selecting 2nd line treatment accordingly in patients with autoimmune encephalitis when multiple antibodies coexist. Despite tumor resection, aggressive immunotherapy may be needed to prevent further deterioration in anti-GABAA receptor encephalitis.

P2, N=63, Not yet recruiting, Tianjin Medical University General Hospital

She was participating in a clinical trial using pembrolizumab and anti-TIGIT EOS-448, due to cancer progression...She was then empirically started on intravenous methylprednisolone for acute eosinophilic pneumonia without confirmatory bronchoscopy as she was at high risk with her previous pneumonectomy...Although bronchoscopy findings are part of AEP's diagnostic criteria, this case underscores the importance of clinical judgment in the prompt initiation of steroids, even without confirmatory bronchoscopy, in rapidly progressing cases. The role of anti-TIGIT therapy in this context remains uncertain.

P4, N=40, Terminated, Erasme University Hospital | N=60 --> 40 | Unknown status --> Terminated

P4, N=540, Not yet recruiting, University of Sydney

P2, N=18, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P3, N=215, Recruiting, Sohag University

P3, N=268, Recruiting, Sohag University

P2, N=60, Recruiting, Masonic Cancer Center, University of Minnesota | Not yet recruiting --> Recruiting

P3, N=174, Recruiting, University Hospital, Antwerp | Not yet recruiting --> Recruiting | Initiation date: Jan 2024 --> May 2024

P2, N=140, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

P1, N=3, Terminated, Fred Hutchinson Cancer Center | Trial completion date: Jul 2032 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2032 --> Feb 2024; Study ended early due to end of funding.

P2, N=60, Not yet recruiting, Masonic Cancer Center, University of Minnesota

P3, N=346, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting

P1/2, N=35, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

P2, N=140, Recruiting, M.D. Anderson Cancer Center | N=100 --> 140

P1, N=47, Active, not recruiting, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trial completion date: Feb 2024 --> Mar 2025

P4, N=89, Terminated, Rutgers, The State University of New Jersey | Suspended --> Terminated; Lack of research staff to recruit participants